Interleukin Genetics, the Massachusetts-based molecular diagnostic startup offering tests through some unique retail channels, narrowed its losses slightly for 2012, but its revenue took a steep plunge in the last quarter of the year. The company reported revenues of $2.2 million for 2012 and a loss from continuing operations of $5.1 million. That compares to a 2011 loss of $5.2 million on revenues of $2.9 million. For the fourth quarter of 2012, Interleukin reported a loss of $1.2 million on revenue of $300,000. That’s a 50 percent drop compared to the year-ago quarter, when revenue was $600,000. The company provides a variety of molecular tests, most aimed for a direct consumer audience rather than for medical necessity. They include tests for an individual’s genetic propensity toward periodontal disease, determining which diet would be the best fit for someone attempting to lose weight, their propensity toward developing heart disease, and for their risk of developing osteoporosis. The nondental tests have been sold through Amway Global since 2009, with Interleukin performing the tests in its laboratory in Waltham. Interleukin also offers testing directly to consumers via Inherent Health subsidiary. Company officials indicated that weak Amway sales had impacted its revenue, particularly in […]
Interleukin Genetics, the Massachusetts-based molecular diagnostic startup offering tests through some unique retail channels, narrowed its losses slightly for 2012, but its revenue took a steep plunge in the last quarter of the year.
The company reported revenues of $2.2 million for 2012 and a loss from continuing operations of $5.1 million. That compares to a 2011 loss of $5.2 million on revenues of $2.9 million.
For the fourth quarter of 2012, Interleukin reported a loss of $1.2 million on revenue of $300,000. That’s a 50 percent drop compared to the year-ago quarter, when revenue was $600,000.
The company provides a variety of molecular tests, most aimed for a direct consumer audience rather than for medical necessity. They include tests for an individual’s genetic propensity toward periodontal disease, determining which diet would be the best fit for someone attempting to lose weight, their propensity toward developing heart disease, and for their risk of developing osteoporosis. The nondental tests have been sold through Amway Global since 2009, with Interleukin performing the tests in its laboratory in Waltham. Interleukin also offers testing directly to consumers via Inherent Health subsidiary.
Company officials indicated that weak Amway sales had impacted its revenue, particularly in the fourth quarter, but that attempts were being made to better integrate the test into Amway’s weight loss programs.
Zacks analyst Brian Marckx has rated Interleukin as an outperform, noting strong sales in its dental line of tests and a recent multimillion-dollar investment in the company by San Francisco-based Delta Dental.
